^
    CANCER:

    Biliary Tract Cancer

    Contact us to learn more about our Premium Content:
    News alerts, weekly reports and conference planners
    Related cancers:
    FGFR2 rearrangement
    Cholangiocarcinoma
    pemigatinib
    Sensitive
    :
    A1
    PRNewswire - 1 week - (New A1)
    FGFR2 fusion
    Cholangiocarcinoma
    pemigatinib
    Sensitive
    :
    A1
    PRNewswire - 1 week - (New A1)
    No biomarker
    Biliary Tract Cancer
    durvalumab
    Sensitive
    :
    A1
    FDA - 3 weeks - (New A1)
    FGFR2 fusion
    Cholangiocarcinoma
    ARQ 087
    Sensitive
    :
    C2
    ESMO 2022 - 3 weeks - (New C3)
    FGFR2 amplification
    Cholangiocarcinoma
    ARQ 087
    Sensitive
    :
    C2
    ESMO 2022 - 3 weeks - (New C3)
    IDH1 R132C + PIK3CA E545K + IDH2 R172K
    Cholangiocarcinoma
    ivosidenib
    Resistant
    :
    C4
    NPJ Precis Oncol - 3 weeks - (New C4)
    FGFR2 M540_I541insMM
    Cholangiocarcinoma
    pemigatinib
    Sensitive
    :
    C4
    Target Oncol - 3 weeks - (New C4)
    FGFR2 rearrangement
    Cholangiocarcinoma
    infigratinib
    Sensitive
    :
    A1
    FGFR2 fusion
    Cholangiocarcinoma
    infigratinib
    Sensitive
    :
    A1
    IDH1 mutation
    Cholangiocarcinoma
    ivosidenib
    Sensitive
    :
    A1
    MSI-H/dMMR
    Biliary Tract Cancer
    pembrolizumab
    Sensitive
    :
    A1
    No biomarker
    Gallbladder Cancer
    GC
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    GemOx
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    CAPOX
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    GEM-CAP
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    FP
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    CAPOX
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    XP
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    FP
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    XP
    Sensitive
    :
    A2
    No biomarker
    Cholangiocarcinoma
    gemcitabine + albumin-bound paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    cisplatin + gemcitabine + albumin-bound paclitaxel
    Sensitive
    :
    A2
    No biomarker
    Gallbladder Cancer
    5-fluorouracil + oxaliplatin
    Sensitive
    :
    A2
    No biomarker
    Cholangiocarcinoma
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    cisplatin + gemcitabine + albumin-bound paclitaxel
    Sensitive
    :
    A2
    BRAF V600E
    Biliary Tract Cancer
    trametinib + dabrafenib
    Sensitive
    :
    A2
    NTRK3 fusion
    Biliary Tract Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Biliary Tract Cancer
    larotrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    Biliary Tract Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Biliary Tract Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    Biliary Tract Cancer
    entrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    Biliary Tract Cancer
    larotrectinib
    Sensitive
    :
    A2
    No biomarker
    Biliary Tract Cancer
    gemcitabine + oxaliplatin
    Sensitive
    :
    A2